Press release
Neurofibrosarcoma Pipeline Appears Robust With 15+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
Stay ahead with the latest insights! Download DelveInsight's comprehensive Neurofibrosarcoma Pipeline Report to explore emerging therapies, key Neurofibrosarcoma Companies, and future Neurofibrosarcoma treatment landscapes @ Neurofibrosarcoma Pipeline Outlook Report [https://www.delveinsight.com/sample-request/neurofibrosarcoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Neurofibrosarcoma Pipeline Report
* In April 2025, University of Florida conducted a phase 2, open label, single arm study will investigate the use of tazemetostat in patients with recurrent/refractory and/or metastatic malignant peripheral nerve sheath tumors.
* In April 2025, Alexander Z. Wei, MD announced a phase II clinical trial will evaluate the safety and efficacy of adding APX005M (a CD40 agonistic monoclonal antibody) to doxorubicin for the treatment of patients with advanced soft tissue sarcoma. The investigators believe that doxorubicin, which is currently the standard of care for most advanced sarcomas, could work better when combined with APX005M, which is a type of immunotherapy.
* DelveInsight's Neurofibrosarcoma Ppipeline report depicts a robust space with 15+ active players working to develop 15+ pipeline therapies for Neurofibrosarcoma treatment.
* The leading Neurofibrosarcoma Companies such as Daiichi Sankyo, Chia Tai Tianqing Pharmaceutical Group, Mirati Therapeutics, Astex Pharmaceuticals, Ascentage Pharma Group, Apexigen, Nobelpharma, Pfizer, SpringWorks Therapeutics, NFlection Therapeutics and others.
* Promising Neurofibrosarcoma Pipeline Therapies such as Ganetespib, Sirolimus, everolimus, bevacizumab, Selumetinib, Tazemetostat, Dasatinib, Doxorubicin, APX005M and others.
Stay ahead with the most recent pipeline outlook for Neurofibrosarcoma. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Neurofibrosarcoma Treatment Drugs [https://www.delveinsight.com/sample-request/neurofibrosarcoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Neurofibrosarcoma Emerging Drugs Profile
* NFX-179: NFlection Therapeutics
NFX-179 is an investigational mitogen-activated protein kinase kinase (MEK) inhibitor. NFX-179 is a ""soft"" (metabolically labile) drug, which, when formulated as NFX-179 Gel for topical application, is designed to concentrate at the dermal site of action but degrade in systemic circulation, thereby significantly reducing side effects compared to systemically available MEK inhibitors.
* Sirolimus: Nobelpharma
Sirolimus inhibits T lymphocyte activation and proliferation that occurs in response to antigenic and cytokine (Interleukin IL-2, IL-4, and IL-15) stimulation by a mechanism that is distinct from that of other immunosuppressants. Sirolimus also inhibits antibody production. In cells, sirolimus binds to the immunophilin, FK Binding Protein-12 (FKBP-12), to generate an immunosuppressive complex. The sirolimus: FKBP-12 complex has no effect on calcineurin activity. This complex binds to and inhibits the activation of the mammalian Target of Rapamycin (mTOR), a key regulatory kinase. This inhibition suppresses cytokine-driven T-cell proliferation, inhibiting the progression from the G1 to the S phase of the cell cycle.
The Neurofibrosarcoma Pipeline report provides insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Neurofibrosarcoma with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Neurofibrosarcoma treatment.
* Neurofibrosarcoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Neurofibrosarcoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Neurofibrosarcoma market.
Explore groundbreaking therapies and clinical trials in the Neurofibrosarcoma Pipeline. Access DelveInsight's detailed report now! @ New Neurofibrosarcoma Drugs [https://www.delveinsight.com/sample-request/neurofibrosarcoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Neurofibrosarcoma Companies
Daiichi Sankyo, Chia Tai Tianqing Pharmaceutical Group, Mirati Therapeutics, Astex Pharmaceuticals, Ascentage Pharma Group, Apexigen, Nobelpharma, Pfizer, SpringWorks Therapeutics, NFlection Therapeutics and others.
Neurofibrosarcoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Oral
* Intravenous
* Subcutaneous
Neurofibrosarcoma Products have been categorized under various Molecule types such as
* Small molecule
* Cell Therapy
* Peptides
* Polymer
* Small molecule
* Gene therapy
Unveil the future of Neurofibrosarcoma Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Neurofibrosarcoma Market Drivers and Barriers [https://www.delveinsight.com/sample-request/neurofibrosarcoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Neurofibrosarcoma Pipeline Report
* Coverage- Global
* Neurofibrosarcoma Companies- Daiichi Sankyo, Chia Tai Tianqing Pharmaceutical Group, Mirati Therapeutics, Astex Pharmaceuticals, Ascentage Pharma Group, Apexigen, Nobelpharma, Pfizer, SpringWorks Therapeutics, NFlection Therapeutics and others.
* Neurofibrosarcoma Pipeline Therapies- Ganetespib, Sirolimus, everolimus, bevacizumab, Selumetinib, Tazemetostat, Dasatinib, Doxorubicin, APX005M and others.
* Neurofibrosarcoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Neurofibrosarcoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Which companies are leading the race in Neurofibrosarcoma Drug development? Find out in DelveInsight's exclusive Neurofibrosarcoma Pipeline Report-access it now! @ Neurofibrosarcoma Emerging Drugs and Major Companies [https://www.delveinsight.com/sample-request/neurofibrosarcoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* Neurofibrosarcoma: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Neurofibrosarcoma- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Sirolimus: Nobelpharma
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* ASTX727: Astex Pharmaceuticals
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I/II)
* MRTX1719: Mirati Therapeutics
* Drug profiles in the detailed report.....
* Preclinical Stage Products
* Drug name: Company name
* Drug profiles in the detailed report.....
* Inactive Products
* Neurofibrosarcoma Key Companies
* Neurofibrosarcoma Key Products
* Neurofibrosarcoma- Unmet Needs
* Neurofibrosarcoma- Market Drivers and Barriers
* Neurofibrosarcoma- Future Perspectives and Conclusion
* Neurofibrosarcoma Analyst Views
* Neurofibrosarcoma Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=neurofibrosarcoma-pipeline-appears-robust-with-15-key-pharma-companies-actively-working-in-the-therapeutics-segment-delveinsight]
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/neurofibrosarcoma-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Neurofibrosarcoma Pipeline Appears Robust With 15+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight here
News-ID: 4006767 • Views: …
More Releases from ABNewswire
Luxury Car Market Size to Reach USD 817.94 Billion by 2031, Driven by Premium El …
Mordor Intelligence has published a new report on the Luxury Car Market offering a comprehensive analysis of trends, growth drivers, and future projections.
Hyderabad - Sep 29th, 2026 - According to Mordor Intelligence, the luxury car market size is expected to grow from USD 603.29 billion in 2026 to USD 817.94 billion by 2031, registering a CAGR of 6.28% during the forecast period. Asia-Pacific is the largest market, while the Middle…
Digital PR outpolls guest posting 48.6% to 16% in survey of 518 link-building sp …
SERPreach analyzes Editorial.Link's 518-expert survey, in which digital PR led guest posting as the most effective link-building tactic, and maps the results to campaign strategy.
MELBOURNE, AUSTRALIA - September 30, 2026 - SERPreach today released an analysis of Editorial.Link's 518-professional survey, in which digital PR drew 48.6% of the vote as the most effective link-building tactic, compared with 16% for guest posting and 12% for linkable assets. The agency's analysis turns…
Rectifi Expands Personal Injury Legal Support Across Ohio, Helping Clients Navig …
OHIO, USA - September 30, 2026 - Have you been hurt in an accident or on the job and now wonder who will fight for you? Rectifi, powered by DiCello Levitt [https://rectifi.law/], steps in when everyday people face powerful insurance companies and large corporations. One wrong step in the first few days can cost you thousands, and what you do first may shape what the claim is worth.
Knowing your legal…
InboxIQo Expands Email List Management Tools for Verification, Cleaning and Cont …
USA - September 30, 2026 - Keeping a contact list organized matters for companies that rely on email communication. Customer records may start to pile up. That's why staying accurate becomes harder. Duplicates can slip in, names and fields can be saved in different ways, and some addresses end up being unusable. All of that can slow down list work and may even delay outreach efforts.
InboxIQo includes tools for email…
More Releases for Neurofibrosarcoma
Neurofibrosarcoma Treatment Market Forecast Through 2026-2033: Emerging Trends, …
The latest Global Neurofibrosarcoma Treatment Market Research Report (2026-2033) delivers high-value insights into the evolving industry landscape, emphasizing growth drivers, revenue streams, and future opportunities. Built using validated research methodologies, the report analyzes market size, revenue performance, production trends, and CAGR projections with a strong focus on accuracy and reliability. It serves as a strategic guide for navigating market complexities, offering a clear view of current conditions alongside emerging innovations…
Neurofibrosarcoma Treatment Market Expected To Reach USD 3317.10 Million by 2032 …
Neurofibrosarcoma Market size was valued at USD 1567.86 Mn in 2024, and is expected to grow at a CAGR of 9.82% from 2025 to 2032, reaching nearly USD 3317.10 Mn by 2032
The Neurofibrosarcoma Treatment Market, often associated with malignant peripheral nerve sheath tumors (MPNST), is gaining increasing attention as healthcare systems around the world continue to strengthen their focus on rare cancers and complex oncology treatment. Neurofibrosarcoma is an aggressive…
Neurofibrosarcoma Market Growing at a CAGR of around 6.3%
Neurofibrosarcoma Market
The Neurofibrosarcoma Market was valued at ~USD 420 million in 2024 and is projected to reach ~USD 780 million by 2034, growing at a CAGR of around 6.3%. Growth is driven by increasing diagnosis of peripheral nerve sheath tumors, rising incidence of neurofibromatosis-associated malignancies, and expanding use of advanced oncology therapies.
Download Full PDF Sample Copy of Market Report
https://exactitudeconsultancy.com/request-sample/71264
Key Market Drivers
• Rising prevalence of malignant peripheral nerve sheath tumors (MPNSTs),…
Adult-onset Still Disease (AOSD) market growing at a CAGR of around 7.7%
The Adult-onset Still Disease (AOSD) market was valued at ~USD 1.2 billion in 2024 and is projected to reach ~USD 2.5 billion by 2034, growing at a CAGR of around 7.7%. Rising diagnosis rates, improved biomarker-based testing, and strong adoption of biologics are the primary growth drivers.
Download Full PDF Sample Copy of Market Report
https://exactitudeconsultancy.com/request-sample/71305
Key Market Drivers
• Increasing awareness and improved identification of AOSD cases.
• Growing use of IL-1 and IL-6 inhibitors…
Neurofibrosarcoma Market Massive Growth opportunity Ahead
Introduction
Neurofibrosarcoma is a rare and aggressive form of cancer that arises from nerve sheath cells, often associated with the nerve fibers in the body. This type of soft tissue sarcoma typically occurs in patients with neurofibromatosis type 1 (NF1), a genetic disorder that predisposes individuals to tumors along the nerves. Neurofibrosarcoma is characterized by malignant tumors that form in or around the nerve fibers, commonly affecting the limbs, abdomen, thoracic…
Neurofibrosarcoma Treatment Market Size in 7MM is expected to grow at a decent C …
DelveInsight's "Neurofibrosarcoma Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Neurofibrosarcoma, historical and forecasted epidemiology as well as the Neurofibrosarcoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Discover which therapies are expected to grab the Neurofibrosarcoma Market Share @ Neurofibrosarcoma Market Outlook- https://www.delveinsight.com/sample-request/neurofibrosarcoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Neurofibrosarcoma Market Report
• In February 2025, Adaptimmune announced a study to…
